Literature DB >> 9727789

Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease.

A Pesci1, B Balbi, M Majori, G Cacciani, S Bertacco, P Alciato, C F Donner.   

Abstract

Cigarette smoking is the most important cause of chronic obstructive pulmonary disease (COPD). Although the precise sequence of events that leads a smoker to experience airway obstruction is not completely clear, airway inflammation is a relevant factor. To investigate airway inflammation, 12 nonatopic smoking COPD patients with a forced expiratory volume in one second (FEV1) < or = 75% predicted and 10 normal nonsmoking subjects (NS) were studied with bronchoscopy and bronchial lavage (BL). Serum immunoglobulin (Ig)E levels of COPD patients correlated with the smoking history (r=0.7, p=0.008). In BL of COPD patients there was an increase of neutrophils (median, range) (COPD 62.6x10(3), 1.2-323, NS 1.35, 0-19.2, p=0.001), eosinophils (COPD 1.6, 0-6.9, NS 0.15, 0-3.7, p=0.035), the levels of interleukin (IL)-8 (COPD 1079 pg x mL(-1), 121-2,500, NS 20.4, 7.2-59, p=0.001), myeloperoxidase (MPO) (COPD 752 microg x L(-1), 11-5,500, NS 22.1, 8-70, p=0.001) and eosinophil cationic protein (ECP) (COPD 21.5 microg x L(-1), 1.8-161, NS 2, 1.8-4.9, p=0.001). Significant correlations were found in BL of COPD patients between IL-8 and neutrophils (p=0.02), MPO and neutrophils (p=0.02), IL-8 and MPO (p=0.0001) and ECP and eosinophils (p=0.02). In addition, the ratios between the BL levels of MPO and the number of neutrophils and between ECP levels and eosinophils were higher in COPD patients than in NS (p=0.03 and 0.01, respectively). These data suggest that cigarette smoke is associated with increased amounts of airway interleukin-8, a chemotactic factor for neutrophils and eosinophils. Recruited neutrophils and eosinophils are activated and they release increased amounts of inflammatory mediators capable of damaging the bronchial tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727789     DOI: 10.1183/09031936.98.12020380

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  72 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 2.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 3.  The Beneficial Effects of Antioxidants in Health And Diseases.

Authors:  Sabina Janciauskiene
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

4.  Efficacy of two breath condensers.

Authors:  A Davidsson; B Schmekel
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils.

Authors:  E-J D Oudijk; E H J Nijhuis; M D Zwank; E A van de Graaf; H J Mager; P J Coffer; J-W J Lammers; L Koenderman
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

Review 6.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8.

Authors:  I S Woolhouse; D L Bayley; R A Stockley
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

8.  Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.

Authors:  G T Verhoeven; J P J J Hegmans; P G H Mulder; J M Bogaard; H C Hoogsteden; J-B Prins
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 9.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

Review 10.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.